Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line

Lori A. Hazlehurst, Nils E. Foley, Mary C. Gleason-Guzman, Miles P. Hacker, Anne E Cress, Lee W. Greenberger, Mariska C. De Jong, William S. Dalton

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Selection for in vitro drug resistance can result in a complex phenotype with more than one mechanism of resistance emerging concurrently or sequentially. We examined emerging mechanisms of drug resistance during selection with mitoxantrone in the human myeloma cell line 8226. A novel transport mechanism appeared early in the selection process that was associated with a 10-fold resistance to mitoxantrone in the 8226/MR4 cell line. The reduction in intracellular drug concentration was ATP-dependent and ouabain-insensitive. The 8226/MR4 cell line was 34-fold cross-resistant to the fluorescent aza-anthrapyrazole BBR 3390. The resistance to BBR 3390 coincided with a 50% reduction in intracellular drug concentration. Confocal microscopy using BBR 3390 revealed a 64% decrease in the nuclear:cytoplasmic ratio in the drug-resistant cell line. The reduction in intracellular drug concentration of both mitoxantrone and BBR 3390 was reversed by a novel chemosensitizing agent, fumitremorgin C. In contrast, fumitremorgin C had no effect on resistance to mitoxantrone or BBR 3390 in the P-glycoprotein- positive 8226/DOX6 cell line. Increasing the degree of resistance to mitoxantrone in the 8226 cell line from 10 to 37 times (8226/MR20) did not further reduce the intracellular drug concentration. However, the 8226/MR20 cell line exhibited 88 and 70% reductions in topoisomerase II β and α expression, respectively, compared with the parental drug sensitive cell line. This decrease in topoisomerase expression and activity was not observed in the low-level drug-resistant, 8226/MR4 cell line. These data demonstrate that low-level mitoxantrone resistance is due to the presence of a novel, energy-dependent drug efflux pump similar to P-glycoprotein and multidrug resistance-associated protein. Reversal of resistance by blocking drug efflux with fumitremorgin C should allow for functional analysis of this novel transporter in cancer cell lines or clinical tumor samples. Increased resistance to mitoxantrone may result from reduced intracellular drug accumulation, altered nuclear/cytoplasmic drug distribution, and alterations in topoisomerase II activity.

Original languageEnglish (US)
Pages (from-to)1021-1028
Number of pages8
JournalCancer Research
Volume59
Issue number5
StatePublished - Mar 1 1999

Fingerprint

Mitoxantrone
Drug Resistance
Cell Line
Pharmaceutical Preparations
Type II DNA Topoisomerase
P-Glycoprotein
Multidrug Resistance-Associated Proteins
Ouabain
Confocal Microscopy
Neoplasms
Adenosine Triphosphate
Phenotype

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hazlehurst, L. A., Foley, N. E., Gleason-Guzman, M. C., Hacker, M. P., Cress, A. E., Greenberger, L. W., ... Dalton, W. S. (1999). Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Research, 59(5), 1021-1028.

Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. / Hazlehurst, Lori A.; Foley, Nils E.; Gleason-Guzman, Mary C.; Hacker, Miles P.; Cress, Anne E; Greenberger, Lee W.; De Jong, Mariska C.; Dalton, William S.

In: Cancer Research, Vol. 59, No. 5, 01.03.1999, p. 1021-1028.

Research output: Contribution to journalArticle

Hazlehurst, LA, Foley, NE, Gleason-Guzman, MC, Hacker, MP, Cress, AE, Greenberger, LW, De Jong, MC & Dalton, WS 1999, 'Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line', Cancer Research, vol. 59, no. 5, pp. 1021-1028.
Hazlehurst LA, Foley NE, Gleason-Guzman MC, Hacker MP, Cress AE, Greenberger LW et al. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. Cancer Research. 1999 Mar 1;59(5):1021-1028.
Hazlehurst, Lori A. ; Foley, Nils E. ; Gleason-Guzman, Mary C. ; Hacker, Miles P. ; Cress, Anne E ; Greenberger, Lee W. ; De Jong, Mariska C. ; Dalton, William S. / Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. In: Cancer Research. 1999 ; Vol. 59, No. 5. pp. 1021-1028.
@article{35f90a8543114c7883815de5c22333e0,
title = "Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line",
abstract = "Selection for in vitro drug resistance can result in a complex phenotype with more than one mechanism of resistance emerging concurrently or sequentially. We examined emerging mechanisms of drug resistance during selection with mitoxantrone in the human myeloma cell line 8226. A novel transport mechanism appeared early in the selection process that was associated with a 10-fold resistance to mitoxantrone in the 8226/MR4 cell line. The reduction in intracellular drug concentration was ATP-dependent and ouabain-insensitive. The 8226/MR4 cell line was 34-fold cross-resistant to the fluorescent aza-anthrapyrazole BBR 3390. The resistance to BBR 3390 coincided with a 50{\%} reduction in intracellular drug concentration. Confocal microscopy using BBR 3390 revealed a 64{\%} decrease in the nuclear:cytoplasmic ratio in the drug-resistant cell line. The reduction in intracellular drug concentration of both mitoxantrone and BBR 3390 was reversed by a novel chemosensitizing agent, fumitremorgin C. In contrast, fumitremorgin C had no effect on resistance to mitoxantrone or BBR 3390 in the P-glycoprotein- positive 8226/DOX6 cell line. Increasing the degree of resistance to mitoxantrone in the 8226 cell line from 10 to 37 times (8226/MR20) did not further reduce the intracellular drug concentration. However, the 8226/MR20 cell line exhibited 88 and 70{\%} reductions in topoisomerase II β and α expression, respectively, compared with the parental drug sensitive cell line. This decrease in topoisomerase expression and activity was not observed in the low-level drug-resistant, 8226/MR4 cell line. These data demonstrate that low-level mitoxantrone resistance is due to the presence of a novel, energy-dependent drug efflux pump similar to P-glycoprotein and multidrug resistance-associated protein. Reversal of resistance by blocking drug efflux with fumitremorgin C should allow for functional analysis of this novel transporter in cancer cell lines or clinical tumor samples. Increased resistance to mitoxantrone may result from reduced intracellular drug accumulation, altered nuclear/cytoplasmic drug distribution, and alterations in topoisomerase II activity.",
author = "Hazlehurst, {Lori A.} and Foley, {Nils E.} and Gleason-Guzman, {Mary C.} and Hacker, {Miles P.} and Cress, {Anne E} and Greenberger, {Lee W.} and {De Jong}, {Mariska C.} and Dalton, {William S.}",
year = "1999",
month = "3",
day = "1",
language = "English (US)",
volume = "59",
pages = "1021--1028",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line

AU - Hazlehurst, Lori A.

AU - Foley, Nils E.

AU - Gleason-Guzman, Mary C.

AU - Hacker, Miles P.

AU - Cress, Anne E

AU - Greenberger, Lee W.

AU - De Jong, Mariska C.

AU - Dalton, William S.

PY - 1999/3/1

Y1 - 1999/3/1

N2 - Selection for in vitro drug resistance can result in a complex phenotype with more than one mechanism of resistance emerging concurrently or sequentially. We examined emerging mechanisms of drug resistance during selection with mitoxantrone in the human myeloma cell line 8226. A novel transport mechanism appeared early in the selection process that was associated with a 10-fold resistance to mitoxantrone in the 8226/MR4 cell line. The reduction in intracellular drug concentration was ATP-dependent and ouabain-insensitive. The 8226/MR4 cell line was 34-fold cross-resistant to the fluorescent aza-anthrapyrazole BBR 3390. The resistance to BBR 3390 coincided with a 50% reduction in intracellular drug concentration. Confocal microscopy using BBR 3390 revealed a 64% decrease in the nuclear:cytoplasmic ratio in the drug-resistant cell line. The reduction in intracellular drug concentration of both mitoxantrone and BBR 3390 was reversed by a novel chemosensitizing agent, fumitremorgin C. In contrast, fumitremorgin C had no effect on resistance to mitoxantrone or BBR 3390 in the P-glycoprotein- positive 8226/DOX6 cell line. Increasing the degree of resistance to mitoxantrone in the 8226 cell line from 10 to 37 times (8226/MR20) did not further reduce the intracellular drug concentration. However, the 8226/MR20 cell line exhibited 88 and 70% reductions in topoisomerase II β and α expression, respectively, compared with the parental drug sensitive cell line. This decrease in topoisomerase expression and activity was not observed in the low-level drug-resistant, 8226/MR4 cell line. These data demonstrate that low-level mitoxantrone resistance is due to the presence of a novel, energy-dependent drug efflux pump similar to P-glycoprotein and multidrug resistance-associated protein. Reversal of resistance by blocking drug efflux with fumitremorgin C should allow for functional analysis of this novel transporter in cancer cell lines or clinical tumor samples. Increased resistance to mitoxantrone may result from reduced intracellular drug accumulation, altered nuclear/cytoplasmic drug distribution, and alterations in topoisomerase II activity.

AB - Selection for in vitro drug resistance can result in a complex phenotype with more than one mechanism of resistance emerging concurrently or sequentially. We examined emerging mechanisms of drug resistance during selection with mitoxantrone in the human myeloma cell line 8226. A novel transport mechanism appeared early in the selection process that was associated with a 10-fold resistance to mitoxantrone in the 8226/MR4 cell line. The reduction in intracellular drug concentration was ATP-dependent and ouabain-insensitive. The 8226/MR4 cell line was 34-fold cross-resistant to the fluorescent aza-anthrapyrazole BBR 3390. The resistance to BBR 3390 coincided with a 50% reduction in intracellular drug concentration. Confocal microscopy using BBR 3390 revealed a 64% decrease in the nuclear:cytoplasmic ratio in the drug-resistant cell line. The reduction in intracellular drug concentration of both mitoxantrone and BBR 3390 was reversed by a novel chemosensitizing agent, fumitremorgin C. In contrast, fumitremorgin C had no effect on resistance to mitoxantrone or BBR 3390 in the P-glycoprotein- positive 8226/DOX6 cell line. Increasing the degree of resistance to mitoxantrone in the 8226 cell line from 10 to 37 times (8226/MR20) did not further reduce the intracellular drug concentration. However, the 8226/MR20 cell line exhibited 88 and 70% reductions in topoisomerase II β and α expression, respectively, compared with the parental drug sensitive cell line. This decrease in topoisomerase expression and activity was not observed in the low-level drug-resistant, 8226/MR4 cell line. These data demonstrate that low-level mitoxantrone resistance is due to the presence of a novel, energy-dependent drug efflux pump similar to P-glycoprotein and multidrug resistance-associated protein. Reversal of resistance by blocking drug efflux with fumitremorgin C should allow for functional analysis of this novel transporter in cancer cell lines or clinical tumor samples. Increased resistance to mitoxantrone may result from reduced intracellular drug accumulation, altered nuclear/cytoplasmic drug distribution, and alterations in topoisomerase II activity.

UR - http://www.scopus.com/inward/record.url?scp=0033104367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033104367&partnerID=8YFLogxK

M3 - Article

C2 - 10070958

AN - SCOPUS:0033104367

VL - 59

SP - 1021

EP - 1028

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 5

ER -